News Lilly trims sales forecast on weaker obesity/diabetes growth Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.
R&D Life Sciences Industry Report 2025 - Part 2 The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.
News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Novo Nordisk swells alliance with AI firm Valo Health Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn.
News Novo Nordisk asks FDA not to allow GLP-1 compounding Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide.
News Lilly invests another $3bn in its manufacturing network Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl